Join to view full profile
1275 York AveNew York, NY 10065
Phone+1 646-227-3813
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Paolo Manfredi, MD is a neurologist in New York, New York. He is currently licensed to practice medicine in New York and Massachusetts.
Education & Training
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Neurology, 1991 - 1993
Stony Brook MedicineInternship, Transitional Year, 1990 - 1991
Univ Genoa- Fac MedClass of 1987
Mass General Brigham/Massachusetts General HospitalFellowship, Pain Medicine
Certifications & Licensure
NY State Medical License 1993 - 2027
MA State Medical License 1994 - 1996
Publications & Presentations
PubMed
- 4 citationsLetter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'.Marco Pappagallo, Thomas R Kosten, Charles W Gorodetzky, Frank J Vocci, Frank L Sapienza
Molecular Psychiatry. 2024-12-01 - 10 citationsEfficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Cont...Maurizio Fava, Stephen M Stahl, Luca Pani, Sara De Martin, Andrew J Cutler
The Journal of Clinical Psychiatry. 2024-06-17 - 1 citationsEffect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017).Clotilde Guidetti, Sara De Martin, Giulia Serra, Massimo Apicella, Luca Pani
The Journal of Clinical Psychiatry. 2024-05-13
Press Mentions
Novel Antidepressant Shows Promise as Add-on TherapyJanuary 6th, 2022- Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in the American Journal of PsychiatryJanuary 5th, 2022
- Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in the American Journal of PsychiatryDecember 22nd, 2021
